Related Experiment Video
Updated: Jun 15, 2026
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
New clues to the molecular pathogenesis of myelodysplastic syndromes
Martin Jädersten1, Eva Hellström-Lindberg
1Center for Experimental Hematology, Department of Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden. martin.jadersten@ki.se
Abstract:
During the past few years our understanding of the genetic basis for the myelodysplastic syndromes (MDS) has improved significantly. A few subgroups have been studied in detail and the genetic alterations are now to a great extent revealed. In 5q- syndrome haploinsufficiency of the ribosomal gene RPS14 appears to cooperate with loss of two micro-RNAs miR-145 and miR-146 to induce key features of the disease. Some mutations are specific for certain categories of MDS while others, such as TET2 seem to occur across the various categories. JAK2 mutations are mainly found in patients with myeloproliferative characteristics. The prognostic implications of most of the novel mutations are not yet fully understood, moreover, functional studies are required in order to understand the interplay between the different lesions; how they give rise to the disease and how some may lead to disease evolution including leukemic transformation. An improved understanding of the pathophysiology of MDS may lead to the identification of suitable targets for future drug development.
Insights
Genetic discoveries significantly advance myelodysplastic syndromes (MDS) understanding. Key mutations like RPS14, TET2, and JAK2 are identified, paving the way for new therapeutic targets.
Area of Science:
- Genetics
- Hematology
- Molecular Biology
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Recent advancements have significantly improved our understanding of the genetic underpinnings of MDS.
- Specific genetic alterations are increasingly being identified in distinct MDS subgroups.
Purpose of the Study:
- To review the current understanding of genetic alterations in myelodysplastic syndromes.
- To highlight key genetic mutations and their roles in MDS pathogenesis.
- To discuss the implications for future drug development and therapeutic strategies.
Main Methods:
- Review of recent scientific literature on MDS genetics.
- Analysis of genetic mutations identified in various MDS subgroups.
- Discussion of the functional roles and prognostic implications of these mutations.
Main Results:
- In 5q- syndrome, RPS14 haploinsufficiency and miR-145/miR-146 loss contribute to disease features.
- TET2 mutations are prevalent across various MDS categories.
- JAK2 mutations are predominantly observed in MDS with myeloproliferative features.
Conclusions:
- Understanding the genetic landscape of MDS is crucial for elucidating disease mechanisms.
- Further functional studies are needed to clarify the interplay of genetic lesions and disease evolution, including leukemic transformation.
- Elucidating MDS pathophysiology may identify novel targets for drug development.
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
02:23Abnormal Proliferation